Text Size

One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease

Baudouin C., De La Maza M.S., Amrane M., Garrigue J.-S., Ismail D., Figueiredo F.C., Leonardi A.


  • 2017
  • European Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Quinze-Vingts National Ophthalmology Hospital, Paris, France; UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France; Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Santen SAS, Evry, France; Department of Ophthalmology, Royal Victoria Infirmary and Newcastle University, Newcastle upon Tyne, United Kingdom; Ophthalmology Unit, Department of Neuroscience, University of Padua, Padua, Italy

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.


Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022